NICE

Thousands of people with advanced lung cancer now have a new treatment option on the NHS in England. We've recommended cemiplimab with chemotherapy for adults with untreated non-small-cell lung cancer. Find out more: nice.org.uk/guidance/indev…

“It has restored my life.” Joanne had suffered from migraines for a decade. Since being prescribed a new tablet recommended by NICE, she hasn't had a single attack. She's one of more than 20,000 people already benefitting. Explore our data story: nice.org.uk/news/articles/…

We’ve recommended tisotumab vedotin for treating cervical cancer that has returned or spread. It belongs to class of medicines called antibody-drug conjugates, which are designed to target and deliver cancer-killing medicine directly to tumour cells: nice.org.uk/guidance/indev…

Hundreds of people with non-small-cell lung cancer that cannot be removed by surgery could now access a new treatment option. We've recommended osimertinib in final guidance published today: nice.org.uk/guidance/ta115…

Fewer than 5% of rare diseases have an approved treatment. The average diagnosis takes over five years. We're proposing a new way forward, and we want to hear from patients, families and carers like you. Open to all, respond before 30th July 2026 – brnw.ch/21x2GHn

Great to see Dr Ranj raising awareness of the shift away from blue inhalers on @BBCMorningLive For every 10,000 people who switch to a combination inhaler, we estimate ▪️1,133 fewer GP visits ▪️144 fewer A&E visits ▪️80 fewer hospital admissions a year 🔗nice.org.uk/news/articles/…

“The technology is here. NICE is ensuring the NHS can use it, for everyone, in every part of the country.” @NICEComms Chief Executive Professor Jonathan Benger on AI, diagnostics, and NHS innovation. 👉 mag.nationalhealthexecutive.com/issue-108-q2/p… #HealthTech #AI #NHS #DigitalHealth

New draft guidance recommends NHS funding for liver perfusion machines, potentially increasing the number of successful transplants for the around 600 people waiting in England. Consultation open until 10 June: nice.org.uk/news/articles/…

CVDPREVENT's latest Data Pack supports ICBs with treating hypertension and lipid management. Get clear insights on NICE guidance implementation and spot opportunities to improve patient outcomes.

"No one can understand the process as well as a patient." Debra survived a heart attack at 38 and joined a NICE committee as a lay member to help shape our digital cardiac rehabilitation guidance. Patient perspective is at the heart of everything we do: indepth.nice.org.uk/from-patient-t…

We’ve recommended a further CAR-T treatment option for people with large B-cell lymphoma, an aggressive form blood cancer, that has relapsed or stopped responding after 2 or more systemic treatments: nice.org.uk/guidance/indev…

Today’s positive guidance has also been welcomed by the executive director of @StomachCancerUK, who highlights the positive difference it can make for patients and their families⬇️

Our recommendation of durvalumab helps to meet an urgent need for treatments that meaningfully extend both the length and quality of patients' lives⬇️

The first immunotherapy for aggressive stomach cancer is now available on the NHS. Durvalumab is recommended for over 1,500 people a year, with evidence showing it helps them live longer and reduces the chance of cancer returning: nice.org.uk/news/articles/…

Hundreds more children with spinal muscular atrophy (SMA) are set to benefit from life-changing NHS treatments. Ezra, now 9, was diagnosed with SMA Type 1 as a baby and is now able to attend mainstream school thanks to early treatment. Read more ⬇️

For people with spinal muscular atrophy and their families, today marks an important milestone. We've recommended routine NHS access to nusinersen and risdiplam, meaning everyone with SMA now has a treatment option routinely available for the first time: nice.org.uk/news/articles/…

Some newborn babies on precautionary antibiotics could complete their treatment at home, cutting hospital stays by up to 2.7 days. New NICE guidance, published today: nice.org.uk/news/articles/…

A new targeted combination treatment for people with a rare form of advanced lung cancer has been recommended in final draft guidance today. Find out more about amivantamab with carboplatin and pemetrexed: nice.org.uk/guidance/indev…

NICE has recommended givinostat for Duchenne muscular dystrophy – helping around 530 people in England walk for longer. It is the first non-steroidal treatment for all DMD genetic variations, funded through the Innovative Medicines Fund. Learn more: nice.org.uk/news/articles/…

A new NHS treatment for rare, aggressive bile duct cancer: nice.org.uk/guidance/ta115… Zanidatamab targets proteins on cancer cells to slow or stop their growth, and in clinical trials helped people live an average of 18 months, compared to 6 months with standard chemotherapy.